YB-0158 (Synonyms: Wnt pathway inhibitor 2) |
Catalog No.GC63303
One-Click Copy Product Info
|
YB-0158 is known as Wnt pathway inhibitor 2. YB-0158 is a peptidomimetic structure with high predicted affinity for Sam68 .
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1144043-83-3
Sample solution is provided at 25 µL, 10mM.
YB-0158 is known as Wnt pathway inhibitor 2. YB-0158 is a peptidomimetic structure with high predicted affinity for Sam68 [1].
YB-0158 elicits a cancer-selective response impeding main cancer stem cell hallmarks [1].
YB-0158 displayed enhanced selective toxicity in colorectal cancer models vs. normal intestinal epithelium progenitor cells. YB-0158 exert negative impact on cancer cell growth by inducing apoptosis and reducing proliferation. YB-0158 eradicated CSCs activity in vivo by a syngeneic mouse-to-mouse serial transplantation assay [2].
References:
[1]. Angelique N. Masibag, Christopher J. Bergin, Joshua R. Haebe, AÏcha Zouggar, Muhammad S. Shah, Tamara Sandouka, Amanda Mendes da Silva, FranÇois M. Desrochers, Aube Fournier-Morin, Yannick D. Benoit.Pharmacological targeting of Sam68 functions in colorectal cancer stem cells. iScience, Volume 24, Issue 12, 17 December 2021, Pages 103442
[2]. Masibag, Angelique Noelline. Characterization of a New Peptidomimetic Compound Modulating Sam68 Functions in Human Colon Cancer Stem Cells. Diss. UniversitÉ d'Ottawa/University of Ottawa, 2021.
| Cell experiment [1]: | |
Cell lines | HT29 cells |
Preparation Method | Cells were treated with DMSO or YB-0158 for 48 hours. As a positive control, each cell line was treated with 1 µM of staurosporine for 6 h. |
Reaction Conditions | 0.2, 0.5µM for 48 hours |
Applications | EdU incorporation confirmed that lower doses of YB-0158 were sufficient to significantly decrease proliferation in human CRC cells. When used at 0.5 µM, YB-0158 also significantly increased apoptosis in CRC cells as represented by activated Caspase-3/7 detection assays |
| Animal experiment [1]: | |
Animal models | C57BL/6 mice accepted subcutaneous injection of MC38 cells into the flanks |
Preparation Method | Seven days post-injection, daily doses of YB-0158 (100mg/kg), or control saline (HBSS vehicle) were intraperitoneally injected in tumor-bearing animals for 14 days. |
Dosage form | Intraperitoneal injection, 100mg/kg |
Applications | No significant differences in primary tumor size were observed upon either YB-0158 in vivo treatments versus saline controls, residual secondary tumors from YB-0158-treated group were significantly smaller versus matched saline controls. |
References: | |
| Cas No. | 1144043-83-3 | SDF | |
| Synonyms | Wnt pathway inhibitor 2 | ||
| Formula | C32H32N7Na2O7P | M.Wt | 703.59 |
| Solubility | DMSO : 100 mg/mL (142.13 mM; Need ultrasonic)|Water : < 0.1 mg/mL (ultrasonic;adjust pH to 1 with 1M HCl) (insoluble) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.4213 mL | 7.1064 mL | 14.2128 mL |
| 5 mM | 284.3 μL | 1.4213 mL | 2.8426 mL |
| 10 mM | 142.1 μL | 710.6 μL | 1.4213 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 20 reference(s) in Google Scholar.)